Depomed cutting one-fourth of staff

Menlo Park-based pharmaceutical firm Depomed Inc. (DEPO), is making staff cuts affecting approximately one-fourth of its staff following disappointing results in a phase 3 study in postherpetic neuralgia.

The company has two products on the market and other candidates in its development pipelines and holds proprietary drug delivery technology for the improvement of oral medications.

The downturn persists

Examiner analysis reveals that San Francisco’s economy has a long road to recovery

It’s the Year of the S.F. Recall — but who pays and who benefits politically?

Recalls may become more frequent and contribute to political destabilization